Mendelian randomization of plasma lipidome, inflammatory proteome and heart failure

被引:0
|
作者
Zheng, Zequn [1 ,2 ]
Tan, Xuerui [1 ,2 ]
机构
[1] Shantou Univ, Affiliated Hosp 1, Med Coll, Dept Cardiol, Shantou, Guangdong, Peoples R China
[2] Shantou Univ, Affiliated Hosp 1, Med Coll, Clin Res Ctr, Shantou, Guangdong, Peoples R China
来源
ESC HEART FAILURE | 2024年 / 11卷 / 06期
基金
中国国家自然科学基金;
关键词
causality; heart failure; inflammatory proteome; lipidome; mediator; Mendelian randomization; RISK; INFERENCE;
D O I
10.1002/ehf2.14997
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims Heart failure (HF) is a global health issue, with lipid metabolism and inflammation critically implicated in its progression. This study harnesses cutting-edge, expanded genetic information for lipid and inflammatory protein profiles, employing Mendelian randomization (MR) to uncover genetic risk factors for HF. Methods We assessed genetic susceptibility to HF across 179 lipidomes and 91 inflammatory proteins using instrumental variables (IVs) from recent genome-wide association studies (GWASs) and proteome-wide quantitative trait loci (pQTL) studies. GWASs involving 47 309 HF cases and 930 014 controls were obtained from the Heart Failure Molecular Epidemiology for Therapeutic Targets (HERMES) Consortium. Data on 179 lipids from 7174 individuals in a Finnish cohort and 91 inflammatory proteins from a European pQTL study involving 14 824 individuals are available in the HGRI-EBI catalogue. A two-sample MR approach evaluated the associations, and a two-step mediation analysis explored the mediation role of inflammatory proteins in the lipid-HF pathway. Sensitivity analyses, including MR-RAPS (robust adjusted profile score) and MR-Egger, ensured result robustness. Results Genetic IVs for 162 lipids and 74 inflammatory proteins were successfully identified. MR analysis revealed a genetic association between HF and 31 lipids. Among them, 18 lipids, including sterol ester (27:1/18:0), cholesterol, 9 phosphatidylcholines, phosphatidylinositol (16:0_20:4) and 6 triacylglycerols, were identified as HF risk factors [odds ratio (OR) = 1.037-1.368]. Cholesterol exhibited the most significant association with elevated HF risk [OR = 1.368, 95% confidence interval (CI) = 1.044-1.794, P = 0.023]. In the inflammatory proteome, leukaemia inhibitory factor receptor (OR = 0.841, 95% CI = 0.789-0.897, P = 1.08E-07), fibroblast growth factor 19 (OR = 0.905, 95% CI = 0.830-0.988, P = 0.025) and urokinase-type plasminogen activator (OR = 0.938, 95% CI = 0.886-0.994, P = 0.030) were causally negatively correlated with HF, whereas interleukin-20 receptor subunit alpha (OR = 1.333, 95% CI = 1.094-1.625, P = 0.004) was causally positively correlated with HF. Mediation analysis revealed leukaemia inhibitory factor receptor (mediation proportion: 23.5%-25.2%) and urokinase-type plasminogen activator (mediation proportion: 9.5%-10.7%) as intermediaries in the lipid-inflammation-HF pathway. No evidence of directional horizontal pleiotropy was observed (P > 0.05). Conclusions This study identifies a genetic connection between certain lipids, particularly cholesterol, and HF, highlighting inflammatory proteins that influence HF risk and mediate this relationship, suggesting new therapeutic targets and insights into genetic drivers in HF.
引用
收藏
页码:4209 / 4221
页数:13
相关论文
共 50 条
  • [41] Heart Failure and Ischemic Stroke: A Bidirectional and Multivariable Mendelian Randomization Study
    Zhang, Luyang
    Liu, Weishi
    Sun, Wenxian
    Wang, Xin
    Tian, Mengke
    Pei, Lu-Lu
    Liu, Kai
    Liang, Jing
    Zhou, Lue
    Lu, Jie
    Ning, Mingming
    Buonanno, Ferdinando S.
    Xu, Yuming
    Song, Bo
    FRONTIERS IN GENETICS, 2021, 12
  • [42] A two-sample Mendelian randomization study of lipidome and lung cancer
    Fan, Zhang
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2025, 252
  • [43] Inflammation and heart failure: a two-sample Mendelian randomization study
    Remmelzwaal, Sharon
    van Oort, Sabine
    Handoko, M. Louis
    van Empel, Vanessa
    Heymans, Stephane R. B.
    Beulens, Joline W. J.
    JOURNAL OF CARDIOVASCULAR MEDICINE, 2022, 23 (11) : 728 - 735
  • [44] Relationships between heart failure, depression, and anxiety: A Mendelian randomization study
    Chen, Xi
    Liang, Xing-Yu
    Zhang, Gui-Lin
    Wei, Shu-Yan
    Zou, Jing-Xia
    Liu, Hao
    Zhang, Hong
    MEDICINE, 2024, 103 (42)
  • [45] Therapeutic Targets for Heart Failure Identified Using Proteomics and Mendelian Randomization
    Henry, Albert
    Gordillo-Maranon, Maria
    Finan, Chris
    Schmidt, Amand F.
    Ferreira, Joao Pedro
    Karra, Ravi
    Sundstrom, Johan
    Lind, Lars
    Arnlov, Johan
    Zannad, Faiez
    Malarstig, Anders
    Hingorani, Aroon D.
    Lumbers, R. Thomas
    CIRCULATION, 2022, 145 (16) : 1205 - 1217
  • [46] Association between walking pace and heart failure: A Mendelian randomization analysis
    Zheng, He
    Wang, Wenbin
    Chen, Chaolei
    Feng, Yingqing
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2024, 34 (12) : 2713 - 2719
  • [47] The genetic association between hyperthyroidism and heart failure: a Mendelian randomization study
    Liu, Jun
    Wu, Gujie
    Li, Shuqi
    Cheng, Lin
    Ye, Xinping
    FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [48] Therapeutic targets for inflammatory bowel disease: proteome-wide Mendelian randomization and colocalization analyses
    Chen, Jie
    Xu, Fengzhe
    Ruan, Xixian
    Sun, Jing
    Zhang, Yao
    Zhang, Han
    Zhao, Jianhui
    Zheng, Jie
    Larsson, Susanna C.
    Wang, Xiaoyan
    Li, Xue
    Yuan, Shuai
    EBIOMEDICINE, 2023, 89
  • [49] Investigating the causal relationship between the plasma lipidome and cholangiocarcinoma mediated by immune cells: a mediation Mendelian randomization study
    Yin, Heng
    Yang, Keli
    Lou, Yan
    Zhao, Yaling
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [50] Systematic proteome-wide Mendelian randomization using the human plasma proteome to identify therapeutic targets for lung adenocarcinoma
    Zhang, Long
    Xiong, Yajun
    Zhang, Jie
    Feng, Yuying
    Xu, Aiguo
    JOURNAL OF TRANSLATIONAL MEDICINE, 2024, 22 (01)